Corporate Website
Africa
Argentina
Asia
Australia
Belgium
Brazil
Bulgaria
Canada (EN)
Chile
China
Colombia
Denmark
Egypt
France
Germany
Greece
Hungary
Indonesia
Italia
India
Japan
Korea
Malaysia
Mexico
Middle East
Netherlands
Peru
Philippines
Poland
Portugal
Romania
Russia
South Africa
Spain
Sweden
Thailand
Tunisia
Turkey
Ukraine
United Kingdom
USA
Vietnam
Ceva Santé Animale confirms its circle of virtuous growth in 2016 >
2016 was a year of sustained organic growth and major acquisitions. Consolidated sales reached €912m as the Ceva Group continued to achieve double-digit growth, cementing its position as the 6th. largest animal health company.
Ceva stresses the need for continued innovation to ensure effective disease control at IPPE 2017 >
Vectormune® ND, vaccine for Newcastle Disease (ND) Cevac IBird®, for Infectious Bronchitis (IB) prevention will continue to lead offerings for effective and easily administered disease control.
Launch of the WVPA-Ceva joint digital library >
Launch of a digital library resource on poultry veterinary medicine
Ceva completes deal to acquire portfolio of Merial swine & cattle vaccines and nonsteroidal anti-inflammatories from Boehringer Ingelheim >
19 January 2017: Ceva Santé Animale today completed the acquisition of a diversified portfolio of products, including swine and cattle vaccines and multi-species nonsteroidal anti-inflammatories from Boehringer Ingelheim .
Ceva acquires Hertape and Inova to enter brazil’s top 5 animal health companies >
Move will increase the group global vaccine footprint with significant entry into the ruminant, Foot and Mouth disease market and a first entry into companion animal vaccines.
C.H.I.C.K Program receives the 1st independently audited quality recognition >
For the first time, an AH company services program receives internationally recognized quality approval from Bureau Veritas.
Ceva posts strong double-digit organic growth once again in first half of 2016 >
Consolidated sales of the Ceva Group reached €455m at the end of June 2016.
Ceva acquires Biovac >
Move will reinforce group’s AMR strategy to find alternative solutions to use of antibiotics.
Ceva Posts Strong Double-Digit growth again in 2014 >
Consolidated sales of the Ceva Group reached €766m at the end of 2014, representing growth of 23% and +14.1% at a constant perimeter and exchange rates.
Another investment of HUF 2 billion from Ceva-Phylaxia >
Ceva-Phylaxia, one of the veterinary market leaders expands its vaccine production plant again.